FDA Grants Orphan Drug Status to TuHURA's Melanoma Therapy; Q1 Results Detail Extended Cash Runway
HURA has more than doubled off its 52-week low of $0.41.
Summary
TuHURA Biosciences reported its first-quarter 2026 financial results and provided a corporate update, highlighted by the receipt of FDA Orphan Drug Designation (ODD) for its lead innate immune agonist, IFx-2.0, for the treatment of stage IIB to stage IV cutaneous melanoma. The company reiterated the previously announced $50 million credit facility, which was detailed in its April 30, 2026 10-K/A filing, confirming it extends the cash runway into 2028. As of March 31, 2026, TuHURA held $6.3 million in cash and equivalents, with net cash outflows from operating activities at $4.4 million for the quarter. The ODD is a significant positive regulatory milestone for a key pipeline asset, potentially offering market exclusivity and tax benefits, while the financial update confirms the impact of recent financing on the company's liquidity. Investors will now watch for further clinical development progress for IFx-2.0 and other pipeline milestones.
At the time of this announcement, HURA was trading at $2.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $147.1M. The 52-week trading range was $0.41 to $4.05. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.